论文部分内容阅读
目的探讨盐酸氨溴索治疗对慢性阻塞性肺疾病(COPD)患者细胞因子和肺功能的影响。方法 COPD急性加重期患者92例随机均分为两组:B组采用常规治疗;A组加用盐酸氨溴索1.2-1.6mg·kg-1·d-1,每天分2-3次缓慢静脉注射。比较两组患者IL-8、IL-10、C-反应蛋白(CRP)和TNF-α等细胞因子以及肺功能的情况。结果两组治疗后IL-8、IL-10、CRP和TNF-α均低于治疗前(P<0.05);A组治疗后IL-8、IL-10、CRP和TNF-α均低于B组(P<0.05)。两组患者治疗后的第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量的百分比(FEV1/FVC)和第1秒用力呼气容积占预计值百分比(FEV1%Pred)均高于治疗前(P<0.05);A组患者治疗后的FEV1、FEV1/FVC和FEV1%Pred均高于B组(P<0.05)。结论在常规治疗基础上加用盐酸氨溴索治疗可降低COPD急性加重期患者血清炎性细胞因子水平,减轻呼吸道炎症反应,改善呼吸功能。
Objective To investigate the effects of ambroxol hydrochloride on cytokines and lung function in patients with chronic obstructive pulmonary disease (COPD). Methods Ninety-two patients with acute exacerbation of COPD were randomly divided into two groups: group B received routine treatment; group A received ambroxol 1.2-1.6 mg · kg-1 · d-1, injection. The IL-8, IL-10, C-reactive protein (CRP) and TNF-α and other cytokines and lung function were compared between the two groups. Results After treatment, the levels of IL-8, IL-10, CRP and TNF-α in both groups were significantly lower than those before treatment (P <0.05). The levels of IL-8, IL-10, CRP and TNF- Group (P <0.05). The FEV1, FEV1 / FVC and FEV1% FEV1 of the two groups after treatment were significantly higher than those of the control group ) Were higher than those before treatment (P <0.05). The FEV1, FEV1 / FVC and FEV1% Pred after treatment in group A were significantly higher than those in group B (P <0.05). Conclusion Ambroxol hydrochloride can reduce serum inflammatory cytokines, relieve airway inflammatory reaction and improve respiratory function in patients with acute exacerbation of COPD.